Abstract: Disclosed are a baffled integrated denitrifying and decarbonizing device with anaerobic bio-nests and a baffled integrated denitrifying and decarbonizing process with anaerobic bio-nests thereof. The wastewater with low carbon-nitrogen ratio first enters anaerobic chamber I, then enters anaerobic chamber II and chamber III to complete anaerobic decarbonization and denitrification. The chambers are provided with modified basalt fiber carrier media to enrich a large number of functional microorganisms, and improve the device in terms of anaerobic treatment efficiency. Fermentation liquid in chamber III then flows back to aerobic chamber IV to complete the nitrification process. Nitrified liquid enters chamber I and mixes with influent for further treatment, and effluent is finally discharged from chamber III. The clapboard and basalt fiber felt in chamber IV can retain and enrich autotrophic/heterotrophic nitrifying bacteria.

Abstract: Examples described herein relate to offload reliable transport management to a network interface device and store packets to be resent, based on received packet receipt acknowledgements (ACKs), into one or more kernel space queues that are also accessible in user space.

Abstract: The present disclosure provides a shield sealing device and a shield sealing method, a fender post is arranged at a shield receiving opening, the shield sealing device is mounted on the fender post, and the shield sealing device comprises: an elastic inner ring, an inner wall of the elastic inner ring adapting to an outer wall of a cutter head of a shield tunneling machine; and a plurality of control units, the plurality of control units being mounted on the fender post, the plurality of control units being arranged in a circumferential direction of the elastic inner ring at intervals, and a driving end of the control part pressing against an outer side of the elastic inner ring so as to extrude or release the elastic inner ring.

Abstract: The present invention relates to a Rho-associated protein kinase inhibitor of formula (I), a pharmaceutical composition comprising the same, a preparation method thereof, and a use of the same in preventing or treating a disease mediated by Rho-associated protein kinase (ROCK).

Abstract: Method, device and computer program product for wireless communication are provided. A method includes: transmitting, by a first wireless communication node, a control message to a second wireless communication node, to control the second wireless communication node to instruct a wireless communication terminal to enter a radio resource control, RRC, inactive mode and transmitting at least one small data transmission, SDT, configuration to the wireless communication terminal.

Abstract: Disclosed is a display substrate, including: a base including a display region and a peripheral region; sub-pixels in the display region; data lines in at least the display region and extending in a first direction and electrically connected to the sub-pixels gate lines in at least the display region and extending in a second direction intersecting with the first direction electrically connected to the sub-pixels pads in the peripheral region; data leads in the peripheral region and electrically connected to the data lines and the pads; a gate driver circuit in the peripheral region and electrically connected to the gate lines; gate drive lines in the peripheral region and electrically connected to the gate driver circuit; gate leads in the peripheral region and extending in the first direction, which are electrically connected to the gate drive lines and the pads and located between the data leads.

Abstract: A P2X3 and/or P2X2/3 receptor antagonist of formula (I), a pharmaceutical composition comprising the same, and a use thereof in preparing a drug for preventing or treating a disease mediated by the P2X3 and/or P2X2/3 receptor antagonist.

Abstract: Compounds of general formula (A) can be used for treating ATR kinase-mediated diseases, for example, hyperplastic diseases such as cancers. Also provided are a pharmaceutical composition of the compounds of general formula (A), a use of the pharmaceutical composition for treating the ATR kinase-mediated diseases and a preparation method for the pharmaceutical composition.

Abstract: The present invention falls within the field of biological medicine, and specifically relates to a method for preventing, alleviating and/or treating fatty liver disease and/or steatohepatitis. The method comprises administering, to an individual in need thereof, an effective amount of a compound of formula (I) or a pharmaceutically acceptable salt, an ester, a stereoisomer, a polymorph, a solvate, an N-oxide, an isotopically labeled compound, a metabolite or a prodrug thereof.

Abstract: Examples described herein relate to a reliable transport protocol for packet transmission using an Address Family of an eXpress Data Path (AF_XDP) queue framework, wherein the AF_XDP queue framework is to provide a queue for received packet receipt acknowledgements (ACKs). In some examples, an AF_XDP socket is to connect a service with a driver for the network device, one or more queues are associated with the AF_XDP socket, and at least one of the one or more queues comprises a waiting queue for received packet receipt ACKs. In some examples, at least one of the one or more queues is to identify one or more packets for which ACKs have been received. In some examples, the network device is to re-transmit a packet identified by a descriptor in the waiting queue based on non-receipt of an ACK associated with the packet from a receiver.

Abstract: Provided herein are compositions and methods for regenerating retinal ganglion cells (RGCs) from retinal neuron cells by activating transcription factors such as one or more of Atoh7, Brn3B, Sox4, Sox11, or Ils1. The retinal neuron cells may be interneuron cells such as amacrine cells, horizontal cells, and bipolar cell. The regenerated RGCs can project axons into discrete subcortical brain regions and establish retina-brain connections. They can respond to visual stimulation and transmit electrical signals into the brain. Therefore, the regenerated RGCs can replace damaged or degenerated RGCs, thereby treating vision impairment or blindness. The methods are likewise applicable to degenerated, damaged, or aged RGCs to stimulate them to regrow functional axons, thereby rejuvenating these RGCs.

Abstract: A display substrate of the present disclosure includes a display region including sub-pixels, data lines, and gate lines; and a circuit region including a first sub-region and a second sub-region opposite to each other at two sides of the display region along a first direction. The first sub-region is provided with a plurality of multiplexing unit groups, each of which includes at least one multiplexing unit. The second sub-region is provided with a plurality of testing unit groups, each of which includes at least one testing unit. The circuit region is further provided with a plurality of driving unit groups, each of which includes at least one driving unit. The driving unit groups and the multiplexing unit groups are alternately arranged along an extending direction of the first sub-region in the first sub-region.

Abstract: Disclosed are a P2X3 and/or P2X2/3 receptor antagonist of formula (I), a pharmaceutical composition containing same, and the use thereof for preventing or treating a disease regulated by the P2X3 and/or P2X2/3 receptor antagonist.

Abstract: A display substrate, a manufacturing method and a display device. In the display substrate, a first power source line includes a transmission portion and a first inlet portion coupled to the transmission portion, the transmission portion is arranged between a display region and the first inlet portion and extends in a first direction, and at least a part of the first inlet portion extends in a second direction. A second power source line includes a peripheral portion and two second inlet portions, the peripheral portion surrounds the display region and is provided with an opening, and two ends of the peripheral portion at the opening are coupled to the two second inlet portions respectively.

Abstract: A display panel and a display apparatus are provided. The display panel includes a supporting layer. The supporting layer includes first spacers and second spacers, which are located on different columns; an anode of at least one of sub pixels corresponding to first spacers extends in a first direction, the first and second spacers extend in a second direction; the first spacers and sub pixels are arranged alternately in the column direction and correspond one-to-one; an orthographic projection of first spacers does not overlap with that of anodes in all sub pixels in the column direction; a first ratio is formed between areas of the first spacers and openings of corresponding sub pixels, a second ratio is formed between an area of the second spacers and an area sum of the openings between two adjacent second spacers in the column direction, the first ratio is different from the second ratio.

Abstract: A new compound of general formula (X) inhibiting and inducing degradation of an EGFR and ALK, and a pharmaceutical composition containing said compound. The compound and the pharmaceutical composition can be used for treating diseases related to the EGFR and the ALK kinase, such as cancer. The present invention further provides the preparation and use of the compound.

Abstract: Embodiments of the prevent invention provide a network access authentication method and device. The method comprises: receiving an authentication request message sent by a first serving network, wherein the authentication request message carries a user equipment pseudonym identifier generated by a user equipment; determining whether a local user equipment pseudonym identifier is asynchronous with the user equipment pseudonym identifier generated by the user equipment; and obtaining, if the determination result is yes, an encrypted international mobile subscriber identity (IMSI) to carry out network access authentication on the user equipment. The embodiments of the present invention can solve the problem that a network access process in the related art does not provide a processing method for the case where the user equipment pseudonym identifier in the user equipment is asynchronous with the user equipment pseudonym identifier in a home network.

Abstract: Provided are a redundant session establishment method and apparatus, a radio bearer establishment method and apparatus, a node, a terminal and a medium. The redundant session establishment method includes: generating redundant user plane resource information, and transmitting the redundant user plane resource information to a master node; and establishing a redundant session corresponding to a redundant session request in a redundant user plane resource according to the redundant session request from the master node, where the redundant session request is a request generated by the master node according to the redundant user plane resource information.

Abstract: A P2X3 and/or P2X2/3 receptor antagonist of formula (I), a pharmaceutical composition comprising the same, and a use thereof in preparing a drag for preventing or treating a disease mediated by the P2X3 and/or P2X2/3 receptor antagonist.

Abstract: A method for treating, resisting and alleviating endometriosis-associated pain, relating to the field of biological medicine, comprising administering, to an individual in need thereof, a therapeutically effective amount of a diaminopyrimidine compound of formula (I) or a pharmaceutically acceptable salt, an ester, a stereoisomer, a polymorph, a solvate, an N-oxide, an isotopically labeled compound, a metabolite or a prodrug thereof.